Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour

État Nombre total Résumé
Négociations actives 43 Non liées à l’oncologie: 30
Liées à l’oncologie: 13
Négociations envisagées 17 Non liées à l’oncologie: 12
Liées à l’oncologie: 5
Négociations terminées 738 Avec lettre d’intention: 635
Sans entente: 103
Négociations qui n’ont pas eu lieu 108

Activités de l’APP dans les quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Axberi/Axberi HP Baxter Corporation Thrombosis and cardiovascular conditions (prevention or treatment)
Velsipity Pfizer Canada ULC Ulcerative Colitis
Ixifi Pfizer Canada ULC Multiple Indications
Truqap AstraZeneca Canada Inc. Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)
Tavneos Otsuka Canada Pharmaceutical Inc. Antineutrophil cytoplasmic antibody-associated vasculitis
Apretude ViiV Healthcare HIV-1 infection, pre-exposure prophylaxis
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Tecentriq SC Hoffmann-La Roche Ltd. Multiple Indications
Koselugo Alexion Pharma GmbH Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas
Keytruda Merck Canada Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinom
Trecondyv Medexus Pharmaceuticals, Inc. As part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies (In combination with fludarabine)
Trikafta Vertex Pharmaceuticals (Canada) Incorporated Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Eylea HD Bayer Inc. Diabetic Macular Edema
Akeega Janssen Inc. Deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC) in adult patients who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. (in combin
Eylea HD Bayer Inc. Age-Related Macular Degeneration
Verzenio Eli Lilly Canada Inc. ​In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Pluvicto Advanced Accelerator Applications Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines